Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Starboard Agreement Tilts Perrigo Toward Rx Generics Sale

Executive Summary

OTC private label giant agrees with Starboard, which owns around 6.7% of Perrigo's shares, to immediately add to Perrigo's board Starboard CEO Jeffrey Smith and two other members recommended by the hedge fund: former Pfizer CEO Jeffrey Kindler and Nestle USA executive Bradley Alford.

Advertisement

Related Content

Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier
Perrigo Positioned To Prosper From Potential Amazon OTC Product Play
Perrigo Glows From Mucinex Private Label Plan, Starboard Plug
Perrigo Draws On OTC Strength For Private Label Nexium 24HR Launch
Perrigo Makes Its Rx Generics Business Look Right At Home
Perrigo Closes Q1 Earnings Saga Trying To Keep Grip On Rx Business
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course
Perrigo Changes Reporting Structure In Latest Stop On Cost-Cutting Trail
Perrigo Puts Tysabri On Block, Generic Topicals Under Microscope
Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119993

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel